Anti-CD70 CAR-expressing T Lymphocytes clinical trials
How each study uses Anti-CD70 CAR-expressing T Lymphocytes is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CD70 CAR-expressing T Lymphocytes studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- CD70 CAR-T cells
- 6
Studies by the year they started
8 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 2
Chongqing Precision Biotech Co., Ltd (6) · Weijia Fang, MD (1) · Zhejiang University (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-CD70 CAR-expressing T Lymphocytes.
- Dec 2026A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic CancerPhase 1 · Chongqing Precision Biotech Co., Ltd
Studies
Open first, then newest update. How each study uses Anti-CD70 CAR-expressing T Lymphocytes is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLERecruitingPhase 1Chongqing Precision Biotech Co., LtdNCT07318259Written as BCMA/CD70 CAR-T cells
- A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid TumorsRecruitingPhase 1Weijia Fang, MDNCT05518253Written as CD70 CAR-T cells
- A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic CancerRecruitingPhase 1Chongqing Precision Biotech Co., LtdNCT06215950Written as CD70 CAR-T cells
- A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid TumorsRecruitingPhase 1Chongqing Precision Biotech Co., LtdNCT06010875Written as CD70 CAR-T cells
- A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-TRecruitingPhase 1Chongqing Precision Biotech Co., LtdNCT05468190Written as CD70 CAR-T cells
- Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal CancerRecruitingPhase 1Chongqing Precision Biotech Co., LtdNCT05420519Written as CD70 CAR-T cells
- A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid TumorsRecruitingPhase 1Chongqing Precision Biotech Co., LtdNCT05420545Written as CD70 CAR-T cells
- CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic DiseasesRecruitingEarly Phase 1Zhejiang UniversityNCT04662294Written as CD70 CAR T-cells